April 11, 2016
Profound Medical Corp., receives CE Mark Approval for TULSA-PRO™
Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique and minimally invasive therapy in prostate care, today announced that the company has received CE Mark approval for the commercial sale of TULSA-PROTM.
View all news
June 15, 2015
Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017
Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company in Phase 2, today announced the close of a US$17 million Series B financing.